Machine signal
Active cluster sell — 7 distinct insiders, $191.1K, window ends Aug 18, 2026.
Figures computed from official regulatory filings — .
Analysttarget 19.83 USD (+75%) · consensus 4.14/5 · 4 buy · 3 hold · 0 sell
Ownershipinsiders 3.96% · institutions 95.2% · short 7.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Keros Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
41 buys351 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Newton Charles W. | Sell | $5.7K | SEC |
| Tanini Annita | Sell | $12.6K | SEC |
| Cho Esther | Sell | $46.2K | SEC |
| Lerner Lorena Raquel | Sell | $36.7K | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $10.3K | conv 12 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $10.6K | conv 26 | SEC |
| Prener Anne | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prener Anne | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $10.2K | conv 26 | SEC |
| Newton Charles W. | Sell | $5.5K | SEC |
| Knowles Julius | Sell | $28.2K | SEC |
| Farzan Nima | Sell | $28.2K | SEC |
| Seth Alpna | Sell | $28.1K | SEC |
| BIENAIME JEAN JACQUEStrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Seth Alpna | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BIENAIME JEAN JACQUEStrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farzan Nima | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GRAY MARY ANN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GRAY MARY ANN | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Knowles Julius | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Knowles Julius | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Seth Alpna | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farzan Nima | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $10.6K | conv 29 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $11.7K | conv 28 | SEC |